When the precautionary principle disrupts 3 years of antibiotic stewardship: Nitrofurantoin in the treatment of urinary tract infections

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 1, 2014, Pages 282-284

  Slekovec, C ^a,b   Leroy, J ^a   Huttner, A ^c   Ruyer, O ^d   Talon, D ^a,b   Hocquet, D ^a,b   Bertrand, X ^a,b  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d Centre Hospitalier de Belfort   (France)

Author keywords

Adverse effects; Fluoroquinolones; Fosfomycin

Indexed keywords

CIPROFLOXACIN; FOSFOMYCIN; LOMEFLOXACIN; NITROFURANTOIN; OFLOXACIN;

ANTIBIOTIC RESISTANCE; HUMAN; LETTER; PRACTICE GUIDELINE; PRESCRIPTION; URINARY TRACT INFECTION;

ADVERSE EFFECTS; FLUOROQUINOLONES; FOSFOMYCIN;

ADOLESCENT; ADULT; AGED; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; FEMALE; FRANCE; HEALTH POLICY; HUMANS; MIDDLE AGED; NITROFURANTOIN; PREVALENCE; URINARY TRACT INFECTIONS; YOUNG ADULT;

EID: 84890404197     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt328     Document Type: Letter

References (10)

1. Réseau Franc-Comtois de lutte contre les infections nosocomiales- Programme régional interdisciplinaire pour la maîtrise des résistances aux anti infectieux (RFCLIN-PRIMAIR). [Urinary Tract Infections in Adults]. http://projet.chu-besancon.fr/rfclin/doc_primair/Bon_usage_de_l_antibio therapie_en_FC.pdf (28 May 2013, date last accessed).
2. Slekovec C, Leroy J, Vernaz-Hegi N et al. Impact of a region wide antimicrobial stewardship guideline on urinary tract infection prescription patterns. Int J Clin Pharm 2012; 34: 325-9.
3. Agence française de sécurité sanitaire des produits de santé (AFSSAPS). [Professional Letter]. http://www.infectiologie.com/site/medias/_documents/consensus/lp-110311-nitrofurantoine.pdf (28 May 2013, date last accessed).
4. WHO Collaborating Centre for Drug Statistics Methodology. Anatomic Therapeutic Chemical (ATC) Classification Index With Defined Daily Doses (DDDs). Oslo, Norway: Norwegian Institute of Public Health, 2001.
5. Direction de l'évaluation des médicaments et des produits biologiques département de pharmacovigilance, Agence française de sécurité sanitaire des produits de santé (AFSSAPS). [National Commission for Pharmacovigilance. Minutes of the Meeting of Tuesday, May 24, 2011]. http://ansm.sante.fr/var/ansm_site/storage/original/application/99a60cf 5689464353d7567fe7c079892.pdf (28 May 2013, date last accessed).
6. Mullard A. Mediator scandal rocks French medical community. Lancet 2011; 377: 890-2.
7. ESAC-Net. Antimicrobial Consumption Rates by Country. http://ecdc. europa.eu/en/activities/surveillance/ESAC-Net/database/Pages/consumptionrates- by-country.aspx (28 May 2013, date last accessed).
8. Gupta K, Hooton TM, Naber KG et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52: e103-20.
9. Shehab N, Patel PR, Srinivasan A et al. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis 2008; 47: 735-43.
10. Gbaguidi-Haore H, Dumartin C, L'Heriteau F et al. Antibiotics involved in the occurrence of antibiotic-resistant bacteria: a nationwide multilevel study suggests differences within antibiotic classes. J Antimicrob Chemother 2013; 68: 461-70.